Cargando…
High-flow nasal cannula for COVID-19 patients: risk of bio-aerosol dispersion
HFNC seems to increase droplet spread, so caution should be taken if it is applied for COVID-19, and adequate protective measures should be provided. Further research on viral spread and risks associated with HFNC therapy in COVID-19 patients is needed. https://bit.ly/3gQjjrY
Autores principales: | Elshof, Judith, Hebbink, Rutger H.J., Duiverman, Marieke L., Hagmeijer, Rob |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453729/ https://www.ncbi.nlm.nih.gov/pubmed/32859674 http://dx.doi.org/10.1183/13993003.03004-2020 |
Ejemplares similares
-
High-flow nasal cannula for COVID-19 patients: risk of bio-aerosol dispersion
por: Li, Jie, et al.
Publicado: (2020) -
High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion
por: Li, Jie, et al.
Publicado: (2020) -
Standard pleural interventions are not high-risk aerosol generating procedures
por: Arnold, David T., et al.
Publicado: (2021) -
COVID-19: minimising risk to healthcare workers during aerosol-producing respiratory therapy using an innovative constant flow canopy
por: Adir, Yochai, et al.
Publicado: (2020) -
High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU
por: Guy, Tiphaine, et al.
Publicado: (2020)